|
RPHM | Onkure Therapeutics, Inc. |
|
|
RPHM | Onkure Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 1.10 |
| Leverage | 8.80% |
| Market Cap | $ 60.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -80.7m |
| Margin | -4108.54% |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. The company is headquartered in San Diego, California.